Edwards Lifesciences Corporation $EW Shares Acquired by Danske Bank A S

Key Points

• Danske Bank A/S boosted its stake in Edwards Lifesciences by 10.2% in Q4 to 346,523 shares (about $29.54 million), while institutional investors own roughly 79.46% of the company.
• Edwards topped Q1 expectations with $0.78 EPS vs. $0.73 est. and $1.65B revenue vs. $1.60B est., set FY2026 guidance of $2.95–$3.05 EPS, and carries a MarketBeat consensus rating of "Moderate Buy" with a $95.65 target.
• Insiders sold 86,058 shares worth about $7.12 million in the last quarter (including notable VP sales), leaving corporate insiders with approximately 0.31% ownership.

Danske Bank A S lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 10.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 346,523 shares of the medical research company's stock after buying an additional 32,200 shares during the period. Danske Bank A S owned approximately 0.06% of Edwards Lifesciences worth $29,541,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Level Four Advisory Services LLC boosted its position in Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after purchasing an additional 119 shares during the period. Colonial Trust Co SC boosted its position in Edwards Lifesciences by 0.4% in the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock valued at $2,504,000 after buying an additional 120 shares during the last quarter. Evermay Wealth Management LLC boosted its position in Edwards Lifesciences by 4.0% in the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company's stock valued at $282,000 after buying an additional 128 shares during the last quarter. Howard Capital Management Inc. boosted its position in Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock valued at $322,000 after buying an additional 132 shares during the last quarter. Finally, Florida Trust Wealth Management Co boosted its position in Edwards Lifesciences by 1.5% in the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company's stock valued at $751,000 after buying an additional 132 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the company's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the transaction, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. The trade was a 2.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares in the company, valued at $1,782,941.44. This represents a 53.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 86,058 shares of company stock worth $7,118,636 in the last quarter. Corporate insiders own 0.31% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an "outperform" rating in a research report on Monday, April 13th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a "hold" rating in a research note on Friday, April 24th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the stock a "hold" rating in a research note on Friday, April 24th. Piper Sandler reiterated an "overweight" rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Barclays restated an "overweight" rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $95.65.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $84.08 on Friday. The stock has a market cap of $48.47 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.11 and a beta of 0.87. The company's fifty day moving average price is $82.08 and its 200-day moving average price is $82.47. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. Edwards Lifesciences's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.